Trends in cancer therapy: Role of monoclonal antibodies

Seminars in Oncology Nursing

Volumn 19, Issue 3, 2003, Pages 169-179

  Schmidt, Kristi V ^a,c   Wood, Barbara A ^b  

^a GENENTECH INC   (United States)

^b Maine Ctr Cancer Med Blood Disord   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; EDRECOLOMAB; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; OREGOVOMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN;

ABDOMINAL PAIN; ANTIBODY PRODUCTION; BLOOD DISEASE; CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL ACTIVATION; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNOCOMPETENT CELL; INFUSION; MEDICAL LITERATURE; NAUSEA; NEUTROPENIA; NURSING; REVIEW; SOLID TUMOR; ANTIBODY SPECIFICITY; FOOD AND DRUG ADMINISTRATION; IMMUNOTHERAPY; NEOPLASM; ONCOLOGY NURSING; STANDARD; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; ONCOLOGIC NURSING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0142058095     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-2081(03)00045-7     Document Type: Article

References (34)

1. Reiger P. Clinical Handbook for Biotherapy. 1999;Jones and Bartlett, Sudbury, MA
2. Davis T.A. New antibodies and strategies for development. Cheson B. Monoclonal Antibody Therapy of Hematologic Malignancies. 2001;243-258 Darwin Scientific, Oxfordshire, United Kingdom
3. Veatch A., Maloney D. Monoclonal antibodies: Mechanisms of action and resistance. Cheson B. Monoclonal Antibody Therapy of Hematologic Malignancies. 2001;13-66 Darwin Scientific, Oxfordshire, United Kingdom
4. Rubin P., Williams J., Okunieff P., et al. Statement of the clinical oncologic problem. Rubin P., Williams J. Clinical Oncology: A Multidisciplinary Approach for Physicians and Students. 8th ed:2001;1-31 Saunders, Philadelphia, PA
5. Leonard J., Kunkel L. Recombinant idiotype conjugated with KLH (ID-KLH) GTOP-99 personalized vaccine for non-Hodgkin's lymphoma. Cancer Invest. 20:2002;72. (abstr)
6. Genentech: Molecular targets in solid tumor therapy. 2002;Genentech BioOncology, South San Francisco, CA
7. Jaramillo M., Rangel C., Grogan T. Immunohistochemistry in leukemias and lymphomas. Faguet G. Hematologic Malignancies: Methods and Techniques. 2001;301-322 Humana, Totowa, NJ
8. Sompayrac L. How the Immune System Works. 1999;Blackwell Science, Malden, MA
9. Rieger P., Green M., Murray J.L. III. Monoclonal antibodies Applications in solid tumors and other diseases. Rieger P. Biotherapy: A Comprehensive Overview. ed 2:2001;317-356 Jones and Bartlett, Sudbury, MA
10. Osterborg A., Dyer M. CAMPATH-1H in the treatment of lymphoid malignancies. Cheson B. Monoclonal Antibody Therapy of Hematologic Malignancies. 2001;135-150 Darwin Scientific, Oxfordshire, United Kingdom
11. Campath Prescribing Information. Available at: http://www.campath.com. (Accessed 1/20/03)
12. Campath Clinical Trials. Available at http://www.clinicaltrials.gov. (Accessed 1/20/03)
13. Czuczman M.S., Grillo-Lopez A.J., White C.A., et al. Treatment of patients with low-grade B cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 17:1999;268-276
14. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med. 346:2002;235-242
15. Vose J.M. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma. J Clin Oncol. 19:2001;389-397
16. Gregory S: Combined fludarabine, mitoxantrone and rituximab achieves a high response as initial treatment for advanced low grade non-Hodgkin's lymphoma. Available at: http://www.hematology.org. (abstr) (Accessed 3/20/03)
17. Martinelli G: Rituximab plus chlorambucil in low grade non-Hodgkin's lymphomas: Clinical results of a phase II study. Available at: http://www.hematology.org (abstr) (Accessed 3/20/03)
18. Venugopal P: ESHAP combined with rituximab and GM-CSF is highly active in relapse/refractory aggressive lymphoma. Available at: http://www.hematology.org (abstr) (Accessed 3/20/03)
19. Ghielmini M: Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: A randomized SAKK trial. Available at: http://www.hematology.org (abstr) (Accessed 3/20/03)
20. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792
21. Robert N, Leyland-Jones B, Asmar L, et al. et al: Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER2/neu positive advanced breast cancer. Available at: http://www.asco.org (abstr) (Accessed 2/1/03)
22. Mylotarg Clinical Trials. Available at: http://clinicaltrials.gov. (Accessed 2/1/03)
23. Witzig T., Wiseman G. Clinical development of 90ytrium-conjugated murine anti-CD20 radioimmunoconjugate (90Y-ibritumomab tiuxetan, 90Y-Zevalin) for B cell non-Hodgkin's lymphomas. Cheson B. Monoclonal Antibody Therapy of Hematologic Malignancies. 2001;203-214 Darwin Scientific, Oxfordshire, United Kingdom
24. Zevalin Clinical Trials. Available at: http://clinicaltrials.gov. (Accessed 2/1/03)
25. Schilder R, Witzig T, Gordon L, et al. et al: 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Available at: http://www.asco.org. (abstr) (Access 1/20/03)
26. Kaminski M, Leonard J, Zelenetz A, et al. et al: Bexxar therapy (tositumomab and iodine I 131 tositumomab) has high response rates in the treatment of bulky low grade (LG) relapsed or refractory non-Hodgkin's lymphoma (NHL). Available at: http://www.asco.org. (abstr) (Accessed 1/20/03)
27. Leonard J. Iodine-131 tositumomab (Bexxar) and HU1D10 (Remitogen) for non-Hodgkin's lymphoma. Cancer Invest. 20:2002;12. (abstr)
28. Hurwitz H., Fehrenbacher L., Cartwright T., et al. Bevacizumab prolongs survival in first-line colorectal cancer Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol (oral presentation). 2003;. (abstr 3646)
29. American Society of Clinical Oncology: Epratuzumab promising against non-Hodgkin's lymphoma. Available at: http://www.pslgroup.com. (Accessed 1/20/03)
30. Leonard J., Coleman M., Matthews J. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma Preliminary response data. Proc Am Soc Clin Oncol. 21:2002;13. (abstr 1060)
31. Hochster H. Cetuximab (Erbitux, C225) antibody therapy of SCCHN, lung and pancreatic cancer. Cancer Invest. 20:2002;78. (abstr)
32. Erbitux. Available at: http://www.imclone.com. (Accessed 1/20/03)
33. Erbitux (Cetuximab) combined with docetaxel in patients with advanced non-small cell lung cancer. Available at: http://www.bms.com. (Accessed 1/20/03)
34. Gardner M., Ambinder E. Molecular-targeted therapies in development. Emerg Ther Oncol. 1:2002;14-16